Related references
Note: Only part of the references are listed.JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles
Jaime A. Castro-Mondragon et al.
NUCLEIC ACIDS RESEARCH (2022)
Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era
Mahmoud Allahham et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis
Kang-Bo Huang et al.
CANCER LETTERS (2021)
STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial
Amir Sonnenblick et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Hypoxia in Breast Cancer-Scientific Translation to Therapeutic and Diagnostic Clinical Applications
Ying Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Denis M. Collins et al.
CLINICAL CANCER RESEARCH (2021)
Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
Bowen Sun et al.
ONCOGENE (2020)
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Ian A. MacNeil et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)
Kathriena Greenwell et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
What turns CREB on? And off? And why does it matter?
Andre Steven et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zhilin Zou et al.
CELL AND BIOSCIENCE (2020)
Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
Przemyslaw Duda et al.
CELLS (2020)
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
Essia Mezni et al.
CANCERS (2020)
Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer
Wuqing Huang et al.
NATURE COMMUNICATIONS (2020)
Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
Jin Hyuk Choi et al.
MEDICINE (2020)
An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer
Joseph Longo et al.
MOLECULAR METABOLISM (2019)
Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer
Kanchan Sonkar et al.
NMR IN BIOMEDICINE (2019)
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN gamma secretion
Bharat K. R. Chaganty et al.
CANCER LETTERS (2018)
Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer
Rasmi R. Mishra et al.
CLINICAL CANCER RESEARCH (2018)
Inhibitors of phosphodiesterase as cancer therapeutics
Ting Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells
Liuting Yang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Phosphodiesterase type 5 and cancers: progress and challenges
Ines Barone et al.
ONCOTARGET (2017)
Targeting Metabolism for Cancer Therapy
Alba Luengo et al.
CELL CHEMICAL BIOLOGY (2017)
Glycerol-3-phosphate Acyltransferase 1 Promotes Tumor Cell Migration and Poor Survival in Ovarian Carcinoma
Rosemarie Marchan et al.
CANCER RESEARCH (2017)
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
Christian F. Singer et al.
CLINICAL CANCER RESEARCH (2017)
Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+advanced breast cancer in BOLERO-1
Masakazu Toi et al.
BREAST CANCER RESEARCH (2017)
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Amy Walz et al.
CLINICAL CANCER RESEARCH (2017)
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
Vinay Varadan et al.
CLINICAL CANCER RESEARCH (2016)
Key Players in Choline Metabolic Reprograming in Triple-negative Breast Cancer
Egidio Iorio et al.
FRONTIERS IN ONCOLOGY (2016)
The Tumor Microenvironment Modulates choline and lipid Metabolism
Noriko Mori et al.
FRONTIERS IN ONCOLOGY (2016)
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
Sara A. Hurvitz et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
Current treatment strategies for inhibiting mTOR in cancer
Francesca Chiarini et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth
I. Azoulay-Alfaguter et al.
ONCOGENE (2015)
Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop
Aleksandra Pandyra et al.
CANCER RESEARCH (2014)
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wei Wang et al.
CURRENT MEDICINAL CHEMISTRY (2014)
A Colon Cancer-derived Mutant of Kruppel-like Factor 5 (KLF5) Is Resistant to Degradation by Glycogen Synthase Kinase 3β (GSK3β) and the E3 Ubiquitin Ligase F-box and WD Repeat Domain-containing 7α (FBW7α)
Agnieszka B. Bialkowska et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The expression of β-catenin in different subtypes of breast cancer and its clinical significance
Shuguang Li et al.
TUMOR BIOLOGY (2014)
EDI3 links choline metabolism to integrin expression, cell adhesion and spreading
Michaela S. Lesjak et al.
CELL ADHESION & MIGRATION (2014)
Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer
Chunmei Wang et al.
CANCER PREVENTION RESEARCH (2013)
Dipyridamole prevents triple-negative breast-cancer progression
Daniela Spano et al.
CLINICAL & EXPERIMENTAL METASTASIS (2013)
Estimation of rat mammary tumor volume using caliper and ultrasonography measurements
Ana Faustino-Rocha et al.
LAB ANIMAL (2013)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis
Joanna D. Stewart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS
J. -H. Chen et al.
NMR IN BIOMEDICINE (2011)
Choline metabolism in malignant transformation
Kristine Glunde et al.
NATURE REVIEWS CANCER (2011)
Frozen robust multiarray analysis (fRMA)
Matthew N. McCall et al.
BIOSTATISTICS (2010)
Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway
Prasanna K. Venkatesh et al.
CARDIOVASCULAR RESEARCH (2010)
Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Jeff Sperinde et al.
CLINICAL CANCER RESEARCH (2010)
Dynamic Telomerase Gene Suppression via Network Effects of GSK3 Inhibition
Alan E. Bilsland et al.
PLOS ONE (2009)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells
David L. Shattuck et al.
CANCER RESEARCH (2008)
The humoral immune system has a key prognostic impact in node-negative breast cancer
Marcus Schmidt et al.
CANCER RESEARCH (2008)
Differential regulation of STAT family members by glycogen synthase kinase-3
Eleonore Beurel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance
Jiangbing Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700
William H. Isacoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1α and mediates its destabilization in a VHL-independent manner
Daniela Fluegel et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt
Hui H. Zhang et al.
MOLECULAR CELL (2006)
Matlnspector and beyond: promoter analysis based on transcription factor binding sites
K Cartharius et al.
BIOINFORMATICS (2005)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer
K Glunde et al.
CANCER RESEARCH (2004)
Increased choline kinase activity in human breast carcinomas:: clinical evidence for a potential novel antitumor strategy
AR de Molina et al.
ONCOGENE (2002)
CREB DNA binding activity is inhibited by glycogen synthase kinase-3β and facilitated by lithium
CA Grimes et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Share Paper
